TY - JOUR
T1 - Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy
AU - Kumar, Vijay Bhooshon
AU - Medhi, Himadri
AU - Yong, Zhang
AU - Paik, Pradip
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells.
AB - In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells.
KW - Cancer therapy
KW - Hollow-mesoporous-PCL
KW - Nanocapsules
KW - Nanoformulation
KW - SiRNA-silencing
UR - http://www.scopus.com/inward/record.url?scp=84959422277&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2015.10.007
DO - 10.1016/j.nano.2015.10.007
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 26554393
AN - SCOPUS:84959422277
SN - 1549-9634
VL - 12
SP - 579
EP - 588
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 3
ER -
